Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.1690
+0.0013 (0.78%)
Jul 2, 2026, 11:07 AM EDT - Market open
Gossamer Bio Revenue
Gossamer Bio had revenue of $16.96M in the quarter ending March 31, 2026, with 71.45% growth. This brings the company's revenue in the last twelve months to $55.54M, down -55.42% year-over-year. In the year 2025, Gossamer Bio had annual revenue of $48.47M, down -57.74%.
Revenue (ttm)
$55.54M
Revenue Growth
-55.42%
P/S Ratio
1.45
Revenue / Employee
$342,821
Employees
162
Market Cap
82.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.47M | -66.23M | -57.74% |
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| MindWalk Holdings | 20.70M |
| Seres Therapeutics | 1.15M |
| Rallybio | 858.00K |
| Entera Bio | 42.00K |
GOSS News
- 1 day ago - Gossamer Bio announces determination of conversion rate for senior secured notes - TheFly
- 1 day ago - Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants - Business Wire
- 6 days ago - Gossamer Bio price target lowered to $2 from $5 at H.C. Wainwright - TheFly
- 15 days ago - Gossamer Bio announces final tender results - TheFly
- 15 days ago - Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
- 23 days ago - Gossamer Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Gossamer Bio announces early tender results, early settlement of solicitation - TheFly
- 4 weeks ago - Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire